Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Value Investor model based on the published strategy of ...

A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history.

Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product ...

Healthcare data sharing is central to the Trusted Exchange Framework and Common Agreement (TEFCA), but to the Native American community, the exchange of information has challenges beyond the current ...

Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...

Nov 17 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on ...

What To Know: The weakness appears linked to Novo Nordisk’s decision to slash the U.S. self-pay price of its popular GLP-1 drugs, Wegovy and Ozempic, from $499 to $349 per month, intensifying pressure ...

Supported by strong balance sheet, program provides flexibility for Company to capitalize on valuation disconnects over the next three years SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc.

THE WHAT? Hims & Hers has rolled out Labs, a diagnostics platform offering up to 120 biomarker tests and personalized action plans through its app. THE DETAILS Labs provides testing across ten health ...